DOA
ARKG icon

D'Orazio & Associates’s ARK Genomic Revolution ETF ARKG Stock Holding History

D'Orazio & Associates’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,000
Closed -$75K – 133
2021
Q3 		$75K Hold
1,000
– – 0.02% 157
2021
Q2 		$93K Hold
1,000
– – 0.02% 124
2021
Q1 		$89K Hold
1,000
– – 0.02% 125
2020
Q4 		$93K Hold
1,000
– – 0.03% 112
2020
Q3 		$64K Buy
+1,000
New +$58.6K 0.03% 122

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

D'Orazio & Associates's ARKG Position: Q4 2021 in Review

D'Orazio & Associates sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 1,000 shares — an estimated $75K sold.

D'Orazio & Associates first reported a position in ARKG in Q3 2020 and held it in 5 quarters. The position peaked at $93K in Q2 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • D'Orazio & Associates reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • D'Orazio & Associates sold 1,000 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $75K.
  • D'Orazio & Associates first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 5 quarters.
  • D'Orazio & Associates's ARK Genomic Revolution ETF position peaked at $93K in Q2 2021.
  • 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on D'Orazio & Associates's 13F filing for Q4 2021, filed 7 Feb 2022.